A small percentage of renal cell carcinomas (RCCs), which are subclassifi ed by histology into clear-cell (75% of cases), papillary (10% -15%), and chromophobe (5%) RCCs and renal oncocytoma (3% -5%), are due to inherited cancer syndromes ( 1 , 2 ) . Each inherited cancer syndrome, such as von HippelLindau (VHL), hereditary papillary cell carcinoma (HPRC), and hereditary leiomyomatosis and renal cell carcinoma (HLRCC), is characterized by the development of specifi c histologic types of renal cancer ( 3 , 4 ) . For example, affected members of families with VHL syndrome frequently develop clear-cell RCCs, whereas patients with HPRC are predisposed to develop type 1 papillary renal carcinomas ( 5 , 6 ) . Patients with HLRCC, by contrast, develop aggressive papillary type 2 renal carcinomas ( 7 -9 ) .
Recently, individuals with Birt-HoggDubé syndrome (BHD), a genodermatosis characterized by fi brofolliculomas (hamartomas of the hair follicle) ( 10 ) and pulmonary cysts ( 11 , 12 ) , were found to have a seven-fold higher risk over the general population of developing kidney neoplasms ( 13 ) . Unlike renal tumors in patients with other inherited kidney cancer syndromes, renal tumors from BHD patients exhibit a spectrum of histologic types, including chromophobe (34%), oncocytoma (5%), clear cell (9%), papillary (2%), and an oncocytic hybrid (50%) with features of chromophobe RCC and renal oncocytoma ( 14 -16 ) . Germline mutations have been identifi ed in a novel gene, BHD, in affected family members ( 17 ) . BHD encodes a protein, folliculin, which is named for the hallmark dermatologic lesions found in BHD patients. All germline mutations identifi ed to date are frameshift or nonsense mutations that are predicted to truncate folliculin, including insertions or deletions of a tract of eight cytosines (C8) in exon 11 ( 17 , 18 ) . Mutations in this " hot spot " are found in the germline of 44% of BHD patients ( 17 ) . The high frequency of germline-inactivating mutations suggests that BHD may act as a tumor suppressor gene. Identifying a somatic " second hit " in the copy of BHD without a germline mutation would support a tumor suppressor function for BHD according to the Knudson two-hit hypothesis.
To address the mutation status of the BHD gene in tumors from BirtHogg-Dubé patients, we analyzed a panel of 77 renal tumors by direct DNA sequence analysis. Tumor samples, as well as matched normal samples, were obtained from 12 affected members of BHD families after renal surgery at the National Cancer Institute (NCI). The protocol was approved by the institutional review board of NCI, and the patients gave written informed consent.
BHD patients were often found to have bilateral, multifocal tumors and underwent staged bilateral partial nephrectomies, providing tumor samples for this study. Out of 77 tumors, 45 frozen tumor samples were sectioned and microdissected manually to obtain both tumor and histologically normal tissue. DNA was isolated in a solution containing 10 m M Tris-HCl (pH 8.0), 1 m M EDTA, 1% Tween 20, and 0.1 mg/mL proteinase K as described ( 19 ) . For the remaining 32 tumors, tissue was no longer available for microdissection, and DNA was obtained from bulk extraction of tissue under high-salt conditions (Puregene kit, Gentra Systems, Minneapolis, MN).
The entire coding region of BHD (exons 4 -14) was sequenced in each tumor sample, following polymerase chain reaction (PCR) amplifi cation. PCR was carried out using genomic primers for the BHD gene as previously described ( 17 ) . A modifi ed primer, SKA3 -1, with the sequence TTCCTGCCGGTTTTGAA GGTG, was substituted for primer SKA3 because it produced more reliable amplifi cation. Reactions were carried out in a 25 μ L volume using Taq PCR Master Mix (Qiagen, Valencia, CA), 0.4 μ M concentrations of each primer, and a volume of input tumor DNA that was empirically determined to result in suffi cient product under standard PCR conditions. Sequencing was carried out using Big Dye Terminator chemistry and run on an ABI Prism 310 Genetic Analyzer (PE/Applied Biosystems, Foster City, CA). Each mutation was verifi ed by repeat PCR and sequencing. To confi rm a somatic BHD mutation in a tumor sample independent of the second gene copy, PCR amplicons that contained a somatic BHD mutation were cloned into the TOPO TA cloning vector or the TOPO XL cloning vector (Invitrogen, Carlsbad, CA) and characterized by sequencing as described above.
The known germline mutation from each patient was detected in every tumor. In addition, either a somatic mutation or loss of heterozygosity (LOH) was * n is the total number of tumors studied for each patient. aa = amino acid; LOH = loss of heterozygosity; SNP = single nucleotide polymorphism. † Histology was determined by analyzing formalin-fi xed, paraffi n-embedded tissue (or frozen sections in cases with a ¶). ‡ MD denotes whether or not the sample was microdissected. § Mutation position is determined from the fi rst nucleotide of the folliculin transcript, GenBank accession number AF517523 ( 17 , 18 , 23 -25 ) . Intronic mutations are designated according to the guidelines set forth in Antonarakis ( 26 ) , and " c. " refers to the numbering of a nucleotide location relating to a reference cDNA sequence.
|| LOH was not found by sequencing in patient 12; however, LOH was detected by microsatellite analysis (data not shown).
In addition to the somatic mutations observed in 41 BHD tumors, LOH was identifi ed at the site of the germline mutation or at an observed single nucleotide polymorphism (SNP) in 13 of 77 (17%) tumors ( Table 1 ; Fig. 1 ). In every case of LOH, the germline mutation was retained, and the wild-type sequence was lost. Interestingly, one of patient 2 ' s tumors appeared to have a partial deletion of the gene, because it exhibited LOH at the germline mutation in exon 9 but not at a SNP in intron 12 ( Table 1 ) . In all, the frequency of a second hit (LOH or a somatic mutation) in the BHD gene was greater than 50%. Together, these results indicate that renal tumors associated with the BHD syndrome arise from cells in which both copies of the BHD gene are inactivated, supporting the hypothesis that BHD is a tumor suppressor gene.
For BHD to fi t the model of a tumor suppressor gene, the second mutation must occur on the wild-type copy of BHD. Although mutation analysis of discrete genomic regions that are amplifi ed by PCR is unable to distinguish between the allele with a germline mutation and the other allele except when the somatic mutation occurs in the same exon as the germline mutation, we observed germline and somatic BHD mutations occurring in the same exon in six of 41 tumors. PCR-amplifi ed products from these exons were subcloned, permitting the identifi cation and sequencing of both BHD alleles. We confi rmed that two BHD mutations, one on each allele, had occurred in these renal tumors ( Fig. 1 ) . These data, combined with the apparent loss of the wild-type allele in 13 tumors, indicate that the fi rst and second mutations occur on different copies of the BHD gene.
However, not all tumors exhibited LOH or somatic mutations. No LOH or somatic mutations were detected in 23 of 77 tumors (30%). In such cases, gene silencing by hypermethylation or mutations in regulatory regions of the BHD gene may play a role in its inactivation. Alternatively, normal cell contamination of tumor tissue may have interfered with detection of somatic mutations in some cases.
In our study, the frequency of somatic mutations and LOH seen differed slightly by renal tumor histology. Whereas 78% of chromophobe tumors (13 mutations plus fi ve LOH in 23 tumors), 72% (27 mutations and seven LOH in 47 tumors) of oncocytic hybrid tumors, and 50% (three mutations and one LOH in eight tumors) of oncocytomas had second hits, no second hit was detected in either of the two clear-cell tumors. It is unclear whether these differences in mutation and LOH frequencies are due to sampling bias, association of a second hit with histologic type, or differences in the degree of normal cell contamination in these histologic types.
Our data showed that the tumors from a given BHD patient have different second hits. A schematic depiction of kidney lesions from a typical BHD patient with mutations superimposed is shown in Figure 2 . Distinct somatic mutations or LOH were observed in the 15 lesions. This patient also developed several renal tumors with mixed histologic features.
Again, LOH and mutation analysis were performed on tissue from the different histologic areas of three such tumors. Within each tumor, the same second hit was observed, regardless of histology. These observations strongly suggest that multiple renal tumors from some BHD patients are independent, clonal events, each arising from a separate and unique second mutation in the BHD gene. However, the three tumors with mixed histologies shared a common somatic mutation in the distinct histologic regions within each tumor. This fi nding suggests that in some cases, a somatic second hit precedes histologic diversifi cation within a single tumor. The molecular mechanism that drives these events is unknown.
Interestingly, somatic mutations as the second hit were more common than LOH in BHD tumors. A similar phenomenon is observed in the adenomatous polyposis coli (APC) tumor suppressor gene. The location of the germline APC mutation is thought to infl uence the type of second hit that occurs ( 20 ) . It has been hypothesized that the combination of fi rst and second hits controls and directs an optimal level of β -catenin activity, referred to as the " just right " or " loose fi t " model ( 21 , 22 ) . To date, there appears to be no relationship between the location of the BHD germline mutation and the nature of the second hit ( Table 1 ) . However, tumors with a wider variety of germline mutations should be examined to resolve this question.
In conclusion, this report is the fi rst comprehensive evaluation of a large number of renal tumors from BHD patients with a known germline BHD mutation. Our results document the high frequency and wide spectrum of second mutations, which strongly support a tumor suppressor role for BHD. Inactivation of both copies of BHD occurred in several histologic types of renal tumors, suggesting that BHD may act at an early stage of renal oncogenesis. Further understanding of the mechanism of BHD-induced tumorigenesis awaits functional studies of the folliculin protein. 
